Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 AI cyclic peptide drug discovery with Bristol Myers Squibb collaboration May 2024; $4.15M Khosla/Uncork/Feld-backed using ML+quantum computing for peptide optimization competing with Relay Therapeutics for pharma licensing.
Menten AI is a San Francisco-based AI drug discovery company — backed by Y Combinator (W20) with $4.15 million in total funding from Y Combinator, Khosla Ventures, Uncork Capital, Feld Ventures, Mana Ventures, Quain Investments, Society Health, and Volpini Ventures — developing peptide and protein therapeutics using machine learning and quantum computing to design novel cyclic peptide drug candidates for pharmaceutical licensing partnerships, completing a research collaboration with Bristol Myers Squibb in May 2024. Founded in 2018, Menten AI applies advanced AI algorithms for cyclic peptide optimization and protein structure design with a business model centered on licensing proprietary algorithms and drug candidates to pharma partners rather than developing therapeutics through full clinical development.
Bucket Robotics builds modular autonomous mobile robots for warehouse and industrial environments, designed for rapid deployment without requiring fixed infrastructure or facility modifications.
Bucket Robotics is an autonomous mobile robot (AMR) company that designs modular, rapidly deployable robots for warehouse automation and industrial material handling. Unlike traditional warehouse automation systems that require significant facility modifications, fixed conveyors, and multi-month installation projects, Bucket Robotics' AMRs navigate dynamically using onboard sensors and AI, allowing deployment in existing facilities without permanent infrastructure changes.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.